Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — 9M 2007 Earnings Presentation
20 slides from Novo Nordisk A/s Class B's earnings presentation, Oct 31, 2007
Slide 1: A focused healthcare company
Conference call 31 October 2007 A focused healthcare company First nine months of 2007 conference call 31 October 2007, 13.00 CET, 12.00 UK time, 8.00 New York time
Slide 2: Agenda
Conference call 31 October 2007 First nine months of 2007 Slide no 1 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results (Jesper Brandgaard, CFO) • Outlook for 2007 (Jesper Brandgaard, CFO)
Slide 3: Forward-looking statements
Conference call 31 October 2007 First nine months of 2007 Slide no 2 Forward-looking statements The above contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. This in particular relates to information included under the headings ‘Outl
Slide 4: Highlights
Conference call 31 October 2007 First nine months of 2007 Slide no 3 Highlights Sales development: • Sales of modern insulins increased by 37% (31% as reported) • Sales of NovoSeven® increased by 10% (4% as reported) • Sales of Norditropin® increased by 12% (7% as reported) • Sales in North America
Slide 5: Growth in Novo Nordisk's insulin franchise looks set to continue
Conference call 31 October 2007 First nine months of 2007 Slide no 4 Growth in Novo Nordisk’s insulin franchise looks set to continue Rapid increase in number of World insulin market growth people with diabetes 2007 2025 Volume: 6.2% 350 DKK: 10.6% 300 2007: 246 million USD: 19.0% 2025: 380 million
Slide 6: Key products continue to drive growth
Conference call 31 October 2007 First nine months of 2007 Slide no 5 Key products continue to drive growth – first nine months of 2007 Sales as reported Growth analysis HRT & other Norditropin® +5% Local currencies Growth Share of +7% growth 5% 8% Diabetes care Modern insulins 37% 71% NovoSeven® +11
Slide 7: Modern insulins
Conference call 31 October 2007 First nine months of 2007 Slide no 6 Modern insulins World market share of total segment Modern insulin sales as reported 50% Levemir® NovoRapid® DKK 1.8bn NovoRapid® NovoMix® +90% DKK 4.8bn 40% Levemir® 18% +21% 30% NovoMix® DKK 3.5bn 34% 48% +25% 20% 10% 0% August A
Slide 8: A continued increase in modern insulin market share
Conference call 31 October 2007 First nine months of 2007 Slide no 7 A continued increase in modern insulin market share IMS world modern insulin Modern insulin penetration market shares, volume 70% Novo Nordisk 60% Eli Lilly Sanofi-Aventis 50% 50% 20% Modern insulin 40% 30% Human insulin 20% 10% 0%
Slide 9: NovoSeven sales development
Conference call 31 October 2007 First nine months of 2007 Slide no 8 NovoSeven® NovoSeven® sales development Key observations • Growth in the first nine months 1,600 of 2007 of 10% in local : 11 % currencies and 4% as reported 1,400 GR CA 1,200 • North American sales main DKK million contributor to
Slide 10: Norditropin sales development
Conference call 31 October 2007 First nine months of 2007 Slide no 9 Norditropin® Norditropin® sales development Key observations • Growth in the first nine months of 2007 of 12% in local 1,000 currencies and 7% as reported 900 % 13 800 A GR : • North American sales main C contributor to growth DKK
Slide 11: Sales by region
Conference call 31 October 2007 First nine months of 2007 Slide no 10 Sales by region - first nine months of 2007 Sales as reported Growth analysis Japan & Oceania -4% Europe Local Growth Share of +6% currencies growth 10% International Europe 6% 17% Operations North America 25% 54% +15% 18% 39% Int
Slide 12: Levemir reinforces modern insulin market leadership in Europe…
Conference call 31 October 2007 First nine months of 2007 Slide no 11 Levemir® reinforces modern insulin market leadership in Europe… Share of total modern insulin Novo Nordisk’s share of long- sales in Europe acting modern insulin in Europe 25% 24% 80% Novo Nordisk Eli Lilly 70% Sanofi-Aventis 20%
Slide 13: … and total market leadership in the US
Conference call 31 October 2007 First nine months of 2007 Slide no 12 … and total market leadership in the US US total insulin market Novo Nordisk’s share of long- share development acting modern insulin in the US 80% 8% 7.7% 70% Novo Nordisk Eli Lilly 7% 60% Sanofi-Aventis 6% 50% 5% 40% 4% 30% 3% 2
Slide 14: Development portfolio – diabetes
Conference call 31 October 2007 First nine months of 2007 Slide no 13 Development portfolio – diabetes Compound Type Indication Phase Levemir® Modern insulin Type 1+2 Launched in US, Europe, etc., approved in JP NovoMix® 50 Modern insulin Type 1+2 Launched in Europe, filed in the US NovoMix® 70 Mode
Slide 15: Development portfolio – haemostasis
Conference call 31 October 2007 First nine months of 2007 Slide no 14 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Heat-stable formulation Filed in Europe and US NovoSeven® Trauma Phase 3 NovoSeven® Prophylaxis Phase 2 completed NovoSeven® Spinal surgery (dose escalation)
Slide 16: Development portfolio - other biopharmaceuticals
Conference call 31 October 2007 First nine months of 2007 Slide no 15 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® Low Dose Hormone replacement therapy Launched in the US, filed in Europe1 Vagifem® Low Dose Hormone replacement therapy Phase 3 completed in the
Slide 17: Financial results
Conference call 31 October 2007 First nine months of 2007 Slide no 16 Financial results DKK million 9M 2007 9M 2006 % change Sales 30,885 28,256 9 Gross profit 23,693 21,252 11 Gross margin 76.7% 75.2% Sales and distribution costs 9,151 8,277 11 Percent of sales 29.6% 29.3% Research and development
Slide 18: Currency development
Conference call 31 October 2007 First nine months of 2007 Slide no 17 Currency development Spot rates Quarterly average Annual average 640 Annual impact on operating 620 profit of a 5% movement in currency (DKK million) USD/DKK 600 2007 2008 580 USD 400 470 USD-related 110 130 560 JPY 150 140 540 GB
Slide 19: Outlook 2007
Conference call 31 October 2007 First nine months of 2007 Slide no 18 Outlook 2007 • Sales growth expectations: Key currency rates • 11-14% in local currencies DKK 2006 2007 Current per 100 average average rate* • 6-9% as reported USD 595 551 518 • Operating profit growth expectations: JPY 5.11 4.64
Slide 20: Investor information
Conference call 31 October 2007 First nine months of 2007 Slide no 19 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its ADRs Novo Allé, DK-2880 Bagsværd are li